Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc., a clinical-stage biotechnology company focused on heart disease therapies, is positioned for a positive outlook due to its promising gene therapy candidates TN-201 and TN-401, with increased projected chances of success from 20% to 30% and from 10% to 15%, respectively. Upcoming readouts in 1H26 and pivotal trial regulatory updates in 2H26 could further validate the efficacy and safety profiles of its therapies, which have already shown significant clinical improvements in patients. The company's innovative approach, evidenced by preclinical data on TN-301, demonstrates potential advantages over existing treatments, enhancing the conviction in its therapeutic portfolio.

Bears say

Tenaya Therapeutics faces significant risks that could adversely affect its stock outlook, primarily linked to potential delays in transitioning preclinical assets to clinical trials and the emergence of safety concerns, such as immune reactions. Additionally, the company may encounter constraints in its manufacturing capacity, which could lead to downward revisions in financial forecasts and negatively impact market sentiment. The variability in patient data, such as the differences in non-sustained ventricular tachycardia (NSVT) burden reductions, raises concerns regarding the consistency and reliability of clinical outcomes that are vital for investor confidence.

Tenaya Therapeutic (TNYA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.